Phase 2 Peripheral Arterial Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with lymphoma who have received no more than 2 previous treatments, or people with multiple myeloma who have received exactly one previous treatment
• People whose cancer responded at least partially to their previous treatment
• People whose doctors consider them suitable candidates for a stem cell transplant using their own stem cells
• People aged 18 to 65 years old
• People who are generally well enough to carry out daily activities with no or minimal limitations (as measured by a standard health scale called ECOG, scoring 0 or 1)
• People whose doctors estimate they are likely to live for more than three months
• People who are capable of having children must be willing to use reliable contraception throughout the study and for 90 days after the last dose, and must have a negative pregnancy blood test within 72 hours before the first dose
• People who are willing and able to provide written consent before any study-related procedures begin

Who may not be able to join:

• People who have previously had a procedure to collect stem cells from their blood (stem cell mobilisation)
• People who have previously had a bone marrow transplant of any kind
• People with lymphoma that has spread into the bone marrow, or people with multiple myeloma where more than 10% of the bone marrow is affected at the time of screening
• People with certain heart conditions, including chest pain (angina), previous heart attack, coronary stents, uncontrolled irregular heartbeat, heart failure, abnormal heart electrical readings (QTc interval over 500ms), reduced heart pumping function (ejection fraction below 60%), or any other heart condition the trial doctor considers a concern
• People with a lung infection that is not under control
• People whose blood test results fall outside acceptable ranges, specifically: low white blood cell count, low neutrophil count (a type of infection-fighting cell), low platelet count, poor kidney function, or elevated liver markers (confirm specific values with trial site)
• People who have taken the drug lenalidomide for more than 4 cycles, or who have taken it within 4 weeks before the stem cell collection process begins
• People who have previously been treated with the drugs fludarabine or melphalan
• People who are planning to receive radiation therapy within 30 days after transplantation
• People who have previously had radiation therapy to the pelvic area
• People who are allergic to mecapegfilgrastim, pegylated G-CSF, G-CSF, or similar products made using E. coli bacteria
• People who are pregnant or breastfeeding
• People who are currently in another clinical trial, or whose last dose of another trial drug was less than 4 weeks (or 5 half-lives of that drug) before the stem cell collection process
• People with any other condition that the trial doctor believes makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.